Merck & Co., Inc. (NYSE:MRK) Shares Sold by Seizert Capital Partners LLC

Seizert Capital Partners LLC lowered its holdings in Merck & Co., Inc. (NYSE:MRK) by 18.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,632 shares of the company’s stock after selling 9,197 shares during the period. Seizert Capital Partners LLC’s holdings in Merck & Co., Inc. were worth $2,538,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Hanson McClain Inc. raised its holdings in shares of Merck & Co., Inc. by 65.0% during the second quarter. Hanson McClain Inc. now owns 7,662 shares of the company’s stock worth $491,000 after acquiring an additional 3,019 shares in the last quarter. Fort Washington Investment Advisors Inc. OH raised its holdings in shares of Merck & Co., Inc. by 133.4% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock worth $9,165,000 after acquiring an additional 82,454 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Merck & Co., Inc. by 2.6% during the second quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock worth $269,678,000 after acquiring an additional 107,201 shares in the last quarter. Honeywell International Inc. raised its holdings in shares of Merck & Co., Inc. by 18.8% during the third quarter. Honeywell International Inc. now owns 633,700 shares of the company’s stock worth $40,576,000 after acquiring an additional 100,500 shares in the last quarter. Finally, Trust Co raised its holdings in shares of Merck & Co., Inc. by 2.8% during the first quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after acquiring an additional 1,852 shares in the last quarter. Institutional investors own 73.63% of the company’s stock.

Several equities analysts have commented on the stock. BMO Capital Markets set a $70.00 target price on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Wednesday, October 11th. JPMorgan Chase & Co. set a $70.00 target price on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Sunday, October 29th. Citigroup raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and set a $72.00 target price on the stock in a research report on Wednesday, October 18th. UBS Group lowered their target price on shares of Merck & Co., Inc. from $72.00 to $67.00 and set a “buy” rating on the stock in a research report on Monday, October 30th. Finally, Sanford C. Bernstein reissued a “buy” rating and set a $64.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, November 15th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Merck & Co., Inc. has an average rating of “Hold” and a consensus target price of $66.29.

Merck & Co., Inc. (NYSE:MRK) traded up $0.05 during midday trading on Thursday, hitting $57.35. 1,632,617 shares of the company traded hands, compared to its average volume of 10,855,414. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57. Merck & Co., Inc. has a twelve month low of $53.63 and a twelve month high of $66.80. The company has a market capitalization of $156,440.00, a PE ratio of 55.68, a PEG ratio of 2.84 and a beta of 0.76.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.08. Merck & Co., Inc. had a negative net margin of 0.49% and a negative return on equity of 0.58%. The business had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. During the same quarter last year, the company earned $1.07 earnings per share. The firm’s revenue was down 2.0% on a year-over-year basis. sell-side analysts predict that Merck & Co., Inc. will post 3.95 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Monday, January 8th. Investors of record on Friday, December 15th were paid a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend was Thursday, December 14th. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.47. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 186.41%.

Merck & Co., Inc. declared that its Board of Directors has approved a share repurchase program on Tuesday, November 28th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

In related news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.25% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Merck & Co., Inc. (NYSE:MRK) Shares Sold by Seizert Capital Partners LLC” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://stocknewstimes.com/2018/01/11/seizert-capital-partners-llc-lowers-stake-in-merck-co-inc-mrk.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply